Cervical cancer remains a leading cause of cancer-related mortality in women, particularly in developing countries. The causal association between genital human papillomavirus (HPV) infection and cervical cancer has been firmly established and the oncogenic potential of certain HPV types has been clearly demonstrated. In recognition of the causal association of cervical cancer with this sexually transmitted viral infection, substantial interest has arisen to develop effective prophylactic and therapeutic vaccines. Prophylactic strategies currently under investigation focus on the induction of effective humoral and cellular immune responses that are potentially protective against subsequent HPV infection. Papillomavirus-like particles have been synthesized to induce neutralizing antibody responses, and impressive immunoprophylactic effects have been demonstrated in both animals and humans. For the treatment of existing HPV infection, techniques to augment cellular immunity by enhancing viral antigen recognition are under investigation, Vaccines targeting the oncogenic proteins E6 and E7 of HPV-16 and -18 are the focus of current clinical trials for cervical cancer patients. It is hoped that the development of successful HPV-specific vaccines will diminish the costs of existing cervical cancer screening programs and reduce the morbidity and mortality associated with the treatment of cervical neoplasias.
3. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA1994;271:1866-1869.
4.
4. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States: American Social Health Association Panel. Sex Transm Dis1999;26:S2-S7.
5.
5. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst1995;87:796-802.
6.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999;189:12-19.
7.
7. de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol1989;63:4898-4903.
8.
8. Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci U S A1989;86:563-567.
9.
9. Barbosa MS, Vass WC, Lowy DR, Schiller JT. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol1991;65:292-298.
10.
10. Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv1992;12:197-217.
11.
11. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science1989;243:934-937.
12.
12. Howley PM. Papillomavirinae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fundamental virology. Philadelphia: Lippincot-Raven, 1996;947-978.
13.
13. von Knebel DM, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: Consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol1994;68:2811-2821.
14.
14. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol1986;67:665-669.
15.
15. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol1990;38:377-382.
16.
16. Shamanin V, Glover M, Rausch C, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res1994;54:4610-4613.
17.
17. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ. Association between HLA-expression and infiltration of immune cells in cervical carcinoma [see comments]. Lab Invest1993;69:651-659.
18.
18. Schiffman MH. Epidemiology of cervical human papillomaviruses. In: zur Hausen H, ed. Human pathogenic papillomaviruses. Heidelberg, Germany: Springer-Verlag, 1994.
19.
19. Whalen RG, Davis HL. DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin Immunol Immunopathol1995;75:1-12.
20.
20. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group [see comments]. N Engl J Med1997;336:1855-1859.
21.
21. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr Opin Immunol1993;5:27-34.
22.
22. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer1995;72:405-411.
23.
23. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today1997;18:89-95.
24.
24. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol1996;62:33-41.
25.
25. Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science1993;261:769-771.
26.
26. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [see comments]. Science1996;274:1363-1366.
27.
27. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination: Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol1996;156:3911-3918.
28.
28. Restifo NP. The new vaccines: Building viruses that elicit antitumor immunity. Curr Opin Immunol1996;8:658-663.
30. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med1998;4:321-327.
31.
31. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest1995;95:341-349.
32.
32. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity1994;1:751-761.
33.
33. Steller MA, Gurski KJ, Murakami M, et al. Cell mediated immunologic responses in cervical and vaginal cancer patients with a lipidated epitope of HPV-16 E7. Clin Cancer Res1998;4:2103-2109.
34.
34. Trudel M, Nadon F, Seguin C, Brault S, Lusignan Y, Lemieux S. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine1992;10:107-112.
35.
35. Morein B. The iscom antigen-presenting system. Nature1988;332:287-288.
36.
36. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine1995;13:1460-1467.
37.
37. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): The first decade. Immunol Cell Biol1996;74:8-25.
38.
38. Schiller JT, Okun MM. Papillomavirus vaccines: Current status and future prospects. Adv Dermatol1996;11:355-381.
39.
39. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun1997;65:3328-3336.
40.
40. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A1992;89:12180-12184.
41.
41. Kirnbauer R, Taub J. Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into viruslike particles. J Virol1993;67:6929-6936.
42.
42. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A1995;92:11553-11557.
43.
43. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol1995;69:3959-3963.
44.
44. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst2001;93:284-292.
45.
45. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol1996;70:3298-3301.
46.
46. Cheng G, Icenogle JP, Kirnbauer R, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis1995;172:1584-1587.
47.
47. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis1997;176:1141-1145.
48.
48. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol1999;73:9609-9613.
49.
49. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol1998;72:8220-8229.
50.
50. Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine2000;18:1051-1058.
51.
51. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol1995;154:5934-5943.
52.
52. Pardoll DM. Genetically engineered tumor vaccines. Ann NY Acad Sci1993;690:301-310.
53.
53. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res1992;58:143-175.
54.
54. Melief CJ, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv1992;13:81-99.
55.
55. Roitt I, Brostoff J, Male D. Cells involved in the immune response. In: Foley F, van den Bergh L, Welcomme C, eds. Immunology. New York 1989;1-18.
56.
56. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol1996;170:101-110.
57.
57. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol1996;156:2918-2926.
58.
58. Zinkernagel RM. Immunology taught by viruses [see comments]. Science1996;271:173-178.
59.
59. Old LJ. Immunotherapy for cancer. Sci Am1996;275:136-143.
60.
60. Irvine KR, Restifo NP. The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol1995;6:337-347.
61.
61. Lee TD. Distribution of HLA antigens in North American caucasions, North American blacks and orientals. In: Lee J, ed. The HLA system: A new approach. New York: Springer-Verlag, 1990;141-178.
62.
62. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C. Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci U S A1992;89:7871-7875.
63.
63. Yoon H, Chung MK, Min SS, et al. Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2: 1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Res1998;54:23-29.
64.
64. Garcia AM, Ortiz-Navarrete VF, Mora-Garcia ML, et al. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. Immunol Lett1999;67:167-177.
65.
65. Alexander M, Salgaller ML, Celis E, et al. Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic HPV-16 E7 epitope. Am J Obstet Gynecol1996;175:1586-1593.
66.
66. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol1993;23:2242-2249.
67.
67. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of phase I-II trial. Eur J Cancer1999;35:946-952.
68.
68. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother2000;23:255-266.
69.
69. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res2000;6:3406-3416.
70.
70. Martinez-Kinader B, Lipford GB, Wagner H, Heeg K. Sensitization of MHC class I-restricted T cells to exogenous proteins: Evidence for an alternative class I-restricted antigen presentation pathway. Immunology1995;86:287-295.
71.
71. Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine1995;13:857-865.
72.
72. Fernando GJ, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol1999;115:397-403.
73.
73. Hariharan K, Braslawsky G, Barnett RS, et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol1998;12:1229-1235.
74.
74. van der Burg SH, Kwappenberg KM, O'Neill T, et al. Preclinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimes. Vaccine2001;19:3652-3660.
75.
75. Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones2000;5:401-405.
76.
76. Thompson HS, Davies ML, Holding FP, et al. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine1999;17:40-49.
77.
77. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis1999;179:612-618.
78.
78. Da Silva DM, Eiben GL, Fausch SC, et al. Cervical cancer vaccines: Emerging concepts and developments. J Cell Physiol2001;186:169-182.
79.
79. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A1998;95:1800-1805.
80.
80. Schafer K, Muller M, Faath S, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer1999;81:881-888.
81.
81. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology1998;240:147-157.
82.
82. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology2000;273:374-382.
83.
83. Mackett M, Smith GL, Moss B. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A1982;79:7415-7419.
84.
84. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology1991;181:62-69.
85.
85. Gao L, Chain B, Sinclair C, et al. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol1994;75(Pt 1):157-164.
86.
86. Boursnell ME, Rutherford E, Hickling JK, et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine1996;14:1485-1494.
87.
87. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol1995;154:4651-4657.
88.
88. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A1995;92:11671-11675.
89.
89. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res1996;56:21-26.
90.
90. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer1998;78:41-45.
91.
91. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet1996;347:1523-1527.
92.
92. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology2000;270:146-161.
93.
93. Toes RE, Hoeben RC, van der Voort EI, et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A1997;94:14660-14665.
94.
94. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther1999;6:73-80.
95.
95. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol1999;73:7877-7881.
96.
96. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther1999;10:2727-2740.
97.
97. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillmavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther1999;6:1972-1981.
98.
98. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res2000;60:1035-1042.
99.
99. Velders MP, Weijzen S, Eiben GL, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol2001;166:5366-5373.
100.
100. Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med1999;5:823-827.
101.
101. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol1991;9:271-296.
102.
102. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med1994;179:1109-1118.
103.
103. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med1996;183:283-287.
104.
104. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [see comments]. J Exp Med1996;183:317-322.
105.
105. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med1995;1:1297-1302.
106.
106. Fields RC, Shimizu K, Mule JJ. murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A1998;95:9482-9487.
107.
107. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res1999;59:1184-1187.
108.
108. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol1999;73:5402-5410.
109.
109. Wang TL, Ling M, Shih IM, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther2000;7:726-733.
110.
110. Tuting T, Deleo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol1997;27:2702-2707.
111.
111. Thornburg C, Boczkowski D, Gilboa E, Nair SK. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy. J Immunother2000;23:412-418.
112.
112. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med1997;3:558-561.
113.
113. National Institutes of Health. Cervical cancer. NIH consensus statement, 14[1], 1-38. 1996 [Monograph].
114.
114. Syrjanen K, Syrjanen S. Epidemiology of human papilloma virus infections and genital neoplasia. Scand J Infect Dis1990;69(Suppl):7-17.
115.
115. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med1997;102:3-8.
117. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: Implications for prevention and projections of future burden. Int J Cancer1993;55:891-903.
118.
118. Centers for Disease Control and Prevention, Prevention of genital HPV infection and sequelae: Report of an external consultants' meeting. Division of STD Prevention. 1-2-1999. Atlanta: Department of Health and Human Services, 1999 [Monograph].
119.
119. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1973-1998, 2001. Bethesda, MD: National Cancer Institute.
